CN103664738B - A kind of crystalline polymorph of carboxamide compounds L MALIC ACID salt - Google Patents
A kind of crystalline polymorph of carboxamide compounds L MALIC ACID salt Download PDFInfo
- Publication number
- CN103664738B CN103664738B CN201210336560.5A CN201210336560A CN103664738B CN 103664738 B CN103664738 B CN 103664738B CN 201210336560 A CN201210336560 A CN 201210336560A CN 103664738 B CN103664738 B CN 103664738B
- Authority
- CN
- China
- Prior art keywords
- indole
- crystal form
- ethyl
- malic acid
- tetrahydrochysene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
The present invention relates to compound shown in Formulas I (Z) N [2 (diethylin) ethyl] 2 methyl 7 (1,2 dihydro 5 fluorine 2 oxo 3H indole 3 subunits) 4,5, two kinds of crystal formations of 6,7 tetrahydrochysene 1H indole 3 carboxylic acid amides L malates, its preparation method and the purposes in the medicine treating excess proliferative disease or malignant tumor thereof.The invention still further relates to the Pharmaceutical composition comprising described crystal formation as active component.
Description
Technical field
The invention belongs to drug world, in particular it relates to pharmaceutically active compound (Z)-N-[2-(diethylamine
Base) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole
Crystalline polymorph, its preparation method of-3-carboxylic acid amides L MALIC ACID salt and be used for treating excess proliferative disease
Purposes in the medicine of disease or malignant tumor.The invention still further relates to comprise medicinal as active component of described crystal formation
Compositions.
Background technology
Pharmaceutically active compound (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(the 1,2-dihydro that the present invention relates to
-5-fluoro-2-oxo-3H-indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides, see: Tang Feng, etc.,
WO2008/067756, (2008), multiple tyrosine kinase is had significant inhibitory activity, and can press down
Make the propagation of multiple man-machine systems, can be used for the preparation of antitumor drug.
In organic compound, many materials often have identical chemical composition, at different thermodynamic conditions
But can form different crystal structures under (temperature, pressure, pH etc.), we are referred to as homogeneity this phenomenon
Polymorphism.These different crystal formations are referred to as " polymorph ".The different polymorph of material has different
Lattice energy, thus it illustrates different chemically and physically characteristics when solid-state, including chemical stability, table
See dissolubility, dissolution velocity, fusing point etc., these character can directly affect crude drug and preparation process and
Produce, and crude drug and the stability of preparation, dissolubility and bioavailability can be affected.For the present invention
Speech, this area also exists such demand: obtain the polymorphic of the high specific surface area being suitable to application.
Summary of the invention
The invention provides (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(the fluoro-2-of 1,2-dihydro-5-shown in Formulas I
Oxo-3H-indole-3-subunit) crystalline polymorphs of-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt
Thing.
(Z) of the present invention-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-
Indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt-pepper noise polymorphs, useRadiation, 2 θ values of the characteristic peak in X-ray powder diffraction spectrogram are: 3.04,
6.18,9.34,17.60 and 26.32, the error of the 2 θ angles of diffraction is 0.2.Preferably, it has basic such as Fig. 1
Shown X-ray powder diffraction spectrogram.This Crystalline polymorph named A type.
(Z) of the present invention-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-
Indole-3-subunit) use of-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt-pepper noise polymorphRadiation, 2 θ values of the characteristic peak in X-ray powder diffraction spectrogram are: 11.62,
12.58,22.40,23.50,24.12 and 25.64, the error of the 2 θ angles of diffraction is 0.2.Preferably, it has
X-ray powder diffraction spectrogram the most as shown in Figure 2.The named Type B of this crystalline polymorph.
(Z) of the present invention-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-
Indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt Type B polymorph INFRARED ABSORPTION
Collection of illustrative plates is at 808cm-1、1190cm-1、1368cm-1、1473cm-1、1516cm-1、1592cm-1、1625
cm-1、1655cm-1、2488cm-1、2629cm-1、2883cm-1、2946cm-1、2980cm-1、3079
cm-1、3268cm-1、3320cm-1There is absworption peak at place.Preferably, its infrared absorption pattern is basic such as Fig. 3
Shown in.
(Z) of the present invention-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-
Indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt Type B polymorph DSC heat absorption
Change at 170 ± 2 DEG C.Preferably Type B polymorph DSC endothermic transition is at 170 ± 1 DEG C.
Present invention also offers the preparation method of the crystalline polymorph (A type, Type B) shown in Formulas I.
The method preparing A type crystalline polymorph: (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-bis-
Hydrogen-5-fluoro-2-oxo-3H-indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides add to, in methanol, add
Heat, to backflow, is gradually added the methanol solution of L MALIC ACID, is cooled to room temperature, continues stirring and crystallizing 4-12h.
Described it is cooled to room temperature, it is therefore preferable to naturally cool to room temperature.Preferably, after stirring and crystallizing 4-12h, pass through
Filter, Cake Wash, 20-60 DEG C of drying under reduced pressure, prepare (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-
Dihydro-5-fluoro-2-oxo-3H-indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt A
Type crystalline polymorph.
The method preparing Type B crystalline polymorph: (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-bis-
Hydrogen-5-fluoro-2-oxo-3H-indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides, L MALIC ACID add
Absolute methanol, ethyl acetate mixed solvent in, heat, reflux, filter, filtrate is cooled to room temperature, continue
Stirring and crystallizing 4-24h.Described filtrate is cooled to room temperature, it is therefore preferable to naturally cool to room temperature.Preferably, stir
After mixing crystallize 4-24h, through filtering, Cake Wash, 20-60 DEG C of drying under reduced pressure, prepare (Z)-N-[2-(diethyl
Amido) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-Yin
Diindyl-3-carboxylic acid amides L MALIC ACID salt Type B crystalline polymorph.
The present invention relates to crystalline polymorph A type, Type B and its mixture and at preparation treatment hyper-proliferative
Purposes in the medicine of property disease or malignant tumor, and relate to the pharmaceutical composition including these crystal formations.
(Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-is described in WO2008/067756
Fluoro-2-oxo-3H-indole-3-subunit) protein kinase activity has by-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides
Regulation effect, can suppress the activity of multiple tyrosine kinase, by quoting, the content of the disclosure is attached to this
Wen Zhong.
The present invention relates to crystalline polymorph A type and Type B and mixture thereof, further relate to include these crystal formations
Pharmaceutical composition.
Term used herein " Pharmaceutical composition " refers to the crystalline polymorphs of therapeutically effective amount compound of formula I
Thing (selected from A type, Type B or A type and the mixture of Type B) and other chemical composition, the most pharmaceutically
Acceptable carrier and the mixture of excipient.Pharmaceutical composition is the administration to organism of the promotion compound.
" pharmaceutically acceptable carrier " refer to organism is not caused obvious zest and do not disturb to
Give the biological activity of compound and the carrier of character or diluent.
" excipient " refers to join in Pharmaceutical composition with the most convenient inert material giving compound
Matter.The example of excipient is including (without limitation) calcium carbonate, calcium phosphate, various saccharides and polytype shallow lake
Powder, cellulose derivative, gelatin, vegetable oil and Polyethylene Glycol.
Therapeutically effective amount, can be to alleviate the disease in object or one or more diseases of disease to a certain extent
Shape, make or one or more physiology of its cause of disease relevant to disease or disease or biochemical parameters partly or completely
The full amount recovering outbreak probability that is normal and/or that reduce disease or disease.
The invention also discloses by (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo
-3H-indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides the method for preparing its L MALIC ACID salt;And
(Z) (1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-is sub-for-N-[2-(diethylin) ethyl]-2-methyl-7-
Base)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides and its L MALIC ACID salt dissolubility, animal in drawing moist, water
The difference of the aspect such as tumour inhibiting rate in internal plasma exposure amount (AUC), animal body.Result shows, L MALIC ACID salt
There is in water more preferable dissolubility, have higher plasma exposure amount, a more preferable tumour inhibiting rate in animal body.
The present invention compares (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-
Indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt A crystal formation and B crystal form stability
Difference, result display B crystal form there is more preferable stability.
The present invention determines (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-
Indole-3-subunit) fusing point of-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt B crystal form, result is
170~171 DEG C.
The present invention also measured weres (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo
-3H-indole-3-subunit) after-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt B crystal form Oral Administration in Rats
Pharmacokinetics, demonstrate preferable bioavailability.
Accompanying drawing explanation
Hereinafter, describe embodiment of the present invention in detail in conjunction with accompanying drawing, wherein:
Fig. 1 is the present invention (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-Yin
Diindyl-3-subunit) XRD figure of-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt A crystal formation;
Fig. 2 is the present invention (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-Yin
Diindyl-3-subunit) XRD figure of-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt B crystal form;
Fig. 3 is the present invention (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-Yin
Diindyl-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt B crystal form IR figure;
Fig. 4 is the present invention (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-Yin
Diindyl-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt B crystal form DSC figure;
Detailed description of the invention
The following examples are to be further illustrated by the present invention rather than limit.
Raw material sources and specification:
(Z) (1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-is sub-for-N-[2-(diethylin) ethyl]-2-methyl-7-
Base)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides press literature method synthesis, see: Tang Feng, etc.,
WO2008/067756, (2008).
Other reagent and solvent are commercial goods, chemical pure or analytical pure, and it is chromatographically pure that HPLC measures agents useful for same.
Embodiment 1:
(Z) (1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-is sub-for-N-[2-(diethylin) ethyl]-2-methyl-7-
Base)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt
By (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-, (1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-is sub-
Base)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides 8.49g(20mmol) it is added to acetonitrile 500ml, dichloromethane
In the mixed liquor of alkane 90ml, ultrasonic to being uniformly dispersed, add L MALIC ACID 3.22g(24mmol), nitrogen
Protection, stirring is warming up to backflow, and after reaction 1h, filtered while hot, filtrate reduced in volume, to dry, adds anhydrous
Ethanol 60ml, ultrasonic filters to after being uniformly dispersed, filter cake after 40 DEG C of vacuum drying the title of yellow solid
Compound 10.39g(18.6mmol), yield 93%.
1H NMR(DMSO-d6) δ ppm:1.15 (6H, t, J=7.2Hz), 1.93 (2H, m), 2.36 (1H,
dd,J=15.5,5.7Hz),2.47(3H,s),2.57(1H,dd,J=15.5,7.7Hz),2.83(2H,t,J=5.8
Hz),2.99(4H,q,J=7.2Hz),3.02(2H,m),3.03(2H,m),3.50(2H,q,J=6.1Hz),
4.03(1H,dd,J=7.7,5.7Hz),6.84(1H,dd,J=8.5,5.1Hz),6.91(1H,td,J=8.6,2.2
Hz),7.37(1H,dd,J=8.9,2.0Hz),7.55(1H,t,J=5.5Hz),10.01(3H,brs),10.89(1H,
s),14.58(1H,s).
Embodiment 2:
(Z) (1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-is sub-for-N-[2-(diethylin) ethyl]-2-methyl-7-
Base)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides (pharmaceutically active compound) and L MALIC ACID salt hygroscopic
Measure
Assay method: take a certain amount of test sample and put a precise weighing (m1) tool plug glass weighing botle in,
Precise weighing (m2);(bottom placement sulfur it is placed in the thermostatic drier of suitable 25 DEG C ± 1 DEG C uncovered for weighing botle
Acid ammonium saturated solution, relative humidity is 80% ± 2%), place 24 hours;Build weighing botle lid, accurate title
Weight (M3).
Draw moist feature description and draw defining of wet weightening finish:
Deliquescence: absorb enough water and divide formation liquid;
Great draw moist: draw wet weightening finish the least by 15%;
Have draw moist: draw wet weightening finish less than 15% and not less than 2%;
Slightly draw moist: draw wet weightening finish less than 2% and not less than 0.2%;
Nothing or moist almost without drawing: draw wet weightening finish less than 0.2%.
Determinand | Draw wet defining |
Pharmaceutically active compound | Moist almost without drawing |
L MALIC ACID salt | Moist almost without drawing |
Embodiment 3:
(Z) (1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-is sub-for-N-[2-(diethylin) ethyl]-2-methyl-7-
Base)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides (pharmaceutically active compound) and L MALIC ACID salt molten in water
The mensuration of Xie Du
Experimental condition:
Chromatograph of liquid: Agilent 1200 highly effective liquid phase chromatographic system (diode array detector)
Chemstation chromatographic work station
Chromatographic column: Aglinet C185μ250×4.6mm
Flowing phase: acetonitrile-water
Detection wavelength: 264nm
Flow velocity: 1.0ml/min
Sample size: 10 μ l
Test method:
At 25 DEG C, take and treat test product about 100mg, accurately weighed, put in 100ml measuring bottle, solubilizer [acetonitrile-
Water (80:20)] appropriate, ultrasonic make dissolving, and with above-mentioned solvent dilution to scale, shake up, precision measures 10 μ l
Inject chromatograph of liquid, record chromatogram;Measure peak area SComparison。
Measure purified water 10ml, be placed in 25ml eggplant type bottle, be gradually added at 25 DEG C and treat that test product is in solution
Till having insoluble solid, ultrasonic 30min, filter off insoluble solid, precision measures filtrate 10 μ l and injects liquid phase
Chromatograph, records chromatogram;Measure peak area STest。
Determinand | Dissolubility (mg/ml) in water |
Pharmaceutically active compound | 0.0200 |
L MALIC ACID salt | 38.6200 |
Embodiment 4:
(Z) (1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-is sub-for-N-[2-(diethylin) ethyl]-2-methyl-7-
Base)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides (pharmaceutically active compound) and the animal body of L MALIC ACID salt thereof
The mensuration of interior plasma exposure amount (AUC)
Testing program:
Laboratory animal: male SD rat
Dosage: 10mg/kg(is based on pharmaceutically active compound)
Salt preparation prescription: pure water dissolves
Pharmaceutically active compound preparation prescription: 0.5%CMC (carboxymethylcellulose) suspendible
Animal experiment packet and process:
Often organize each 3 male rats, body weight 180~210g.Gastric infusion blood sampling time point is: 5min, 15min,
30min, 45min, 1h, 2h, 4h, 6h, 10h and 24h, taken blood 250 μ about L in liver by orbital venous plexus
In elementization test tube, centrifugal, take blood plasma 100 μ L and analyze for LC-MS.
AUC test result:
Tested material | AUC(0-t)(μg/L*h) |
Pharmaceutically active compound | 127.9 |
L MALIC ACID salt | 1489.4 |
Embodiment 5:
(Z) (1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-is sub-for-N-[2-(diethylin) ethyl]-2-methyl-7-
Base)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides (pharmaceutically active compound) and L MALIC ACID salt thereof is to people's colon
The curative effect of cancer HT-29 Nude Mice
Testing program:
Laboratory animal: BALB/cA-nude nude mouse, 6-7 week, ♀
Dosage: 40mg/kg(is based on pharmaceutically active compound)
L MALIC ACID salt preparation prescription: pure water dissolves
Pharmaceutically active compound preparation prescription: 0.5%CMC (carboxymethylcellulose) suspendible
Experimental procedure:
Nude mouse subcutaneous vaccination human colon carcinoma HT-29 cell, treats that tumor growth is to 150-250mm3After, will be dynamic
Thing is randomly divided into 3 groups (d0), continuous gastric infusion 21 days, surveys weekly 2-3 tumor volume, records data.
Gross tumor volume (V) computing formula is: V=1/2 × a × b2, wherein a, b represent length and width respectively.
Relative tumor rate of increase T/C (%)=(T-T0)/(C-C0) × 100, the tumor at the end of wherein T, C are experiment
Volume;T0、C0Gross tumor volume when starting for experiment, tumour inhibiting rate=1-T/C (%).
Experimental result:
It is administered | Tumour inhibiting rate (%) |
Pharmaceutically active compound | 40 |
L MALIC ACID salt | 54 |
Embodiment 6:(Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-
Subunit) preparation of-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt A crystal formation:
By (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-, (1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-is sub-
Base)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides 4.24g(10mmol) it is added in methanol 40mL, stirring,
It is heated to backflow;Add to L MALIC ACID 2.50g, in methanol 20mL, be made into methanol solution, slowly drop to
Backflow system.After completion of dropwise addition, continue stirring reaction 15min, stop heating, naturally cool to room temperature, and
Continuing stirring 8h in room temperature, separate out a large amount of yellow solid, filter, filter cake is washed through dehydrated alcohol (5mL*3)
Wash, 40 DEG C of vacuum drying, obtain solid 4.93g.
The XRD figure of A crystal formation is shown in Fig. 1.
Embodiment 7:(Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-
Subunit) preparation of-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt B crystal form:
Successively by (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-
Subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides 466g (1.10mol), absolute methanol 11.65L, ethyl acetate
0.26L, L MALIC ACID 178.48g (1.33mol) are added in 20L reaction bulb, and solution stirring is warming up to backflow, instead
Answer about 1h, filtered while hot.Filtrate stirring is warming up to backflow, clarifies completely to reactant liquor, closes heating,
Temperature fall, to room temperature, continues stirring 12h, filters, obtain solid 564g after filter cake 40 DEG C vacuum drying.
The XRD figure of B crystal form, infrared absorption spectroscopy, DSC endothermic transition figure are shown in Fig. 2-4.
Embodiment 8:(Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-
Subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt A crystal formation, the X-ray powder of B crystal form
Diffraction is identified
Instrument: Rigaku company D/max-2500/PC type turns target X-ray diffractometer
Pipe pressure: 40kV
Pipe flow: 100mA
Rotary target: copper target
Beam wavelength: CuK α,
Slit system: DS:1 °;SS:1 °;RS:0.15mm
Monochromator device: graphite curved-crystal monochromator
Sweep limits: 0.00-40.00 °
Scanning speed: 10.00 °/min
A type and Type B crystal formation use Cu-K α radiation, represent spending 2 θ (error of the 2 θ angles of diffraction is for 0.2)
X-ray powder diffraction spectrogram see Fig. 1 and Fig. 2 respectively, the position (2 θ) at its peak and relative peak intensities are visible
Tables 1 and 2, in the table, is 1 to 12 to be classified as the most weak by peak intensity, and 13 to 32 is weak, 33
Being general to 64,65 to 87 is strong, and 88 to 100 is very strong (with reference to ZL 01817064.1).
The numerical value of A type
The numerical value of Type B
Embodiment 8 (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-
Subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt A crystal formation, the stability of B crystal form
Take and treat that test agent (A, B crystal form), in weighing botle, uncovered is placed in 85 DEG C, RH(relative humidity) > 90%
Environment in, respectively at 3 days, 122 days sampling, HPLC method measure have related substance, result is:
The impact on stability of A, B crystal form
Conclusion: A crystal form samples accelerated test occurs in that two more than 0.1% newly-increased impurity after 3 days, and original
Impurity has to a certain degree to be increased, and the total purity of sample declines about 1%;B crystal form sample accelerated test is after 122 days,
Sample purity is declined slightly (decline degree is 0.14%), and B crystal form has more preferable stability.
Embodiment 9:(Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-
Subunit) infrared spectrum (IR) of-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt B crystal form:
Instrument: BRUKER Vector 33 infrared spectrometer
Prepared by sample: KBr tabletting
The infrared absorption pattern of Type B crystal formation (pressing potassium bromide troche) is shown in Fig. 3, and it is at 430cm-1、450cm-1、
504cm-1、555cm-1、556cm-1、594cm-1、631cm-1、674cm-1、726cm-1、736cm-1、
772cm-1、781cm-1、789cm-1、808cm-1、820cm-1、844cm-1、892cm-1、908cm-1、
935cm-1、958cm-1、981cm-1、1008cm-1、1018cm-1、1053cm-1、1080cm-1、1103
cm-1、1134cm-1、1156cm-1、1176cm-1、1190cm-1、1234cm-1、1261cm-1、1277
cm-1、1304cm-1、1324cm-1、1368cm-1、1340cm-1、1421cm-1、1439cm-1、1456
cm-1、1473cm-1、1516cm-1、1592cm-1、1625cm-1、1655cm-1、2488cm-1、2629
cm-1、2761cm-1、2883cm-1、2946cm-1、2980cm-1、3047cm-1、3079cm-1、3268
cm-1、3320cm-1There is absworption peak at place.
Embodiment 10 (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-
Subunit) Differential scanning calorimetry (DSC) of-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt B crystal form:
Instrument: NETZSCH DSC 204 type differential thermal analyzer
Temperature range: 30-250 DEG C
Programming rate: 10 DEG C/min
The thermal analysis curue of Type B crystal differential scanning calorimetry is shown in Fig. 4, and its DSC endothermic transition is at 170 DEG C.
Embodiment 11 (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-
Subunit) Differential scanning calorimetry (DSC) of-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt B crystal form
Fusing point:
Instrument: Tianjin precision instrument factory YRT-3 type melting point apparatus
Heating rate: 1.0 DEG C/min
Type B crystalline melting point is 170~171 DEG C.
Pharmacokinetics after embodiment 12 Oral Administration in Rats B crystal form raw material
Weigh appropriate B crystal form raw material, with 10% Tween 80/0.5% benzyl alcohol/5% ethanol/84.5% normal saline
It is configured to desired concn.
Healthy SD rat 12, male and female half and half, body weight 200 ~ 250g, is tested by Chinese Academy of Sciences Shanghai
Animal center offer [production licence number: SCXK(Shanghai) 2007 ~ 0005, use credit number SYXK
(Shanghai) 2008 ~ 0049], it is randomly divided into 2 groups.Fasting 12h before being administered, freely drinks water.With 10 and 20mg/kg
Dosage gavage respectively give Type B raw material (administration volume is 10mL/kg), in be administered before and administration after 0.25,
0.5,1.0,2.0,3.0,5.0,7.0,9.0,12 and 24h through eyeball rear vein beard extracting vein blood 0.2mL,
Putting in heparinised tubes, 3500rpm is centrifuged 10min, separated plasma, and-70 ° of C preserve to be measured.
Plasma sample assay method
Instrument: Synapt type quadrupole rod-flight time tandem mass spectrometer (Q-TOF MS), is furnished with electron spray electricity
From source (ESI source), Waters, US;UPLC liquid chromatographic system, including binary infusion pump, certainly
Dynamic injector, column oven, degasser and UV-detector, Waters, US.Data acquisition uses Waters
Masslynx 4.1 software of company, data analysis uses MDF function, Metabolynx and Mass
FragmentTMSoftware.
Chromatographic condition
Chromatographic column is Acquity UPLC HSS T3column(2.1 × 100mm I.D., 1.8 μm particle diameters),
Waters, US;Column temperature is 40 ° of C;Flowing is acetonitrile-water mutually;Flow velocity is 0.4mL/min.
Result of study
Conclusion: after rat single oral gavage gives 10 and 20mg/kg Type B raw materials, the plasma drug level of medicine
Peak time tmaxIt is respectively 3.17 and 2.67h;Reach peak concentration CmaxIt is respectively 68.5 and 454ng/mL;
AUC0-tIt is respectively 349 and 2237ng h/mL;Plasma elimination half life t1/2It is respectively 2.44 and 2.10h.
After dose modification, with AUC0-tCalculating, rat single oral gavage gives the exhausted of 10 and 20mg/kg Type B raw materials
Bioavailability is respectively 12.9% and 41.4%.
Claims (7)
1. (Z)-N-[2-(diethylin) the ethyl]-2-methyl-7-(1 shown in a Formulas I, 2-dihydro-5-fluoro-2-oxo-3H-indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides L MALIC ACID salt B crystal form
It is characterized in that: useRadiation, it has basic X-ray powder diffraction spectrogram as shown in Fig. 2.
2.
According to the B crystal form described in claim 1, it is characterised in that infrared absorption pattern is at 808cm-1、1190cm-1、1368cm-1、1473cm-1、1516cm-1、1592cm-1、1625cm-1、1655cm-1、2488cm-1、2629cm-1、2883cm-1、2946cm-1、2980cm-1、3079cm-1、3268cm-1、3320cm-1There is absworption peak at place.
3.
According to the B crystal form described in claim 1, it is characterised in that infrared absorption pattern is the most as shown in Figure 3.
4.
According to the B crystal form described in claim 1, it is characterised in that 170 ± 2 ° of C of DSC endothermic transition.
5.
A kind of prepare any one of claim 1-4 described in the method for B crystal form, it is characterized in that: (Z)-N-[2-(diethylin) ethyl]-2-methyl-7-(1,2-dihydro-5-fluoro-2-oxo-3H-indole-3-subunit)-4,5,6,7-tetrahydrochysene-1H-indole-3-carboxylic acid amides, L-malic acid add in the mixed solvent of absolute methanol, ethyl acetate, heat, reflux, filter, filtrate is cooled to room temperature, continues stirring and crystallizing 4-24h.
6.
A kind of pharmaceutical composition, described pharmaceutical composition includes the B crystal form according to any one of claim 1-4 of therapeutically effective amount, and one or more pharmaceutically acceptable carrier or excipient.
7.
The B crystal form according to any one of claim 1-4 purposes in the medicine of preparation treatment excess proliferative disease or malignant tumor.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210336560.5A CN103664738B (en) | 2012-09-12 | 2012-09-12 | A kind of crystalline polymorph of carboxamide compounds L MALIC ACID salt |
PCT/CN2013/083278 WO2014040528A1 (en) | 2012-09-12 | 2013-09-11 | Crystallized polymorph of carboxylamide compound l-malate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210336560.5A CN103664738B (en) | 2012-09-12 | 2012-09-12 | A kind of crystalline polymorph of carboxamide compounds L MALIC ACID salt |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103664738A CN103664738A (en) | 2014-03-26 |
CN103664738B true CN103664738B (en) | 2016-07-13 |
Family
ID=50277622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210336560.5A Expired - Fee Related CN103664738B (en) | 2012-09-12 | 2012-09-12 | A kind of crystalline polymorph of carboxamide compounds L MALIC ACID salt |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103664738B (en) |
WO (1) | WO2014040528A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012084A1 (en) * | 1998-08-31 | 2000-03-09 | Sugen, Inc. | Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity |
BRPI0413281A (en) * | 2003-08-06 | 2006-10-10 | Sugen Inc | Geometrically restricted 3-cyclopentylidene-1,3, dihydroindol-2-ones as potent protein kinase inhibitors |
CN101200446A (en) * | 2006-12-15 | 2008-06-18 | 江苏先声药物研究有限公司 | 3-pyrrole ring caproic subunit-2-dihydroindolone derivatives and uses thereof |
CN101195601A (en) * | 2006-12-04 | 2008-06-11 | 江苏先声药物研究有限公司 | 2-dihydro indolone derivant, preparation method and application thereof |
JP5542445B2 (en) * | 2006-12-04 | 2014-07-09 | 江▲蘇▼先声▲薬▼物研究有限公司 | 3-pyrrolocyclohexylidene-2-dihydroindolinone derivatives and uses thereof |
CN102675184A (en) * | 2011-03-15 | 2012-09-19 | 江苏先声药物研究有限公司 | Salt form of tyrosine kinase inhibitor |
-
2012
- 2012-09-12 CN CN201210336560.5A patent/CN103664738B/en not_active Expired - Fee Related
-
2013
- 2013-09-11 WO PCT/CN2013/083278 patent/WO2014040528A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2014040528A1 (en) | 2014-03-20 |
CN103664738A (en) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103282365B (en) | (8S, 9R) 5 fluorine 8 (4 fluorophenyl) 9 (base of 1 methyl 1H, 1,2,4 triazoles 5) 8,9 dihydro 2H pyridos [4,3,2 de] phthalazines 3 (7H) ketone toluene fulfonate of crystallization | |
CN110402244A (en) | The salt of LSD1 inhibitor | |
JP6971390B2 (en) | Crystal form, manufacturing method and use of deuterated AZD9291 | |
CN110759908B (en) | N-benzenesulfonyl benzamide compound for inhibiting Bcl-2 protein and composition and application thereof | |
CN104098586B (en) | The crystal formation of the thienopyridine lipid derivant of nitrile group-containing, its preparation method and application | |
JP6717947B2 (en) | Crystals of quinazoline derivative and preparation method thereof | |
CN107759600A (en) | Crystallization as the Pyrrolopyrimidine compounds of JAK inhibitor | |
CN113336768B (en) | Multi-target tyrosine kinase inhibitor | |
CN106232602A (en) | Deuterated quinazolinones and comprise the pharmaceutical composition of this compound | |
CN103664738B (en) | A kind of crystalline polymorph of carboxamide compounds L MALIC ACID salt | |
US9018242B2 (en) | Salt form of tyrosine kinase inhibitor | |
CN105440083B (en) | A kind of lobaplatin crystal, preparation method and medicinal application | |
CN103819461B (en) | N-[the chloro-4-of 3-(3-fluorine benzyloxy) phenyl]-6-[5-[[2-(methanesulfinyl) ethyl] amino] methyl]-2-furyl]-4-quinazoline amine polymorph and preparation method thereof | |
CN109516991A (en) | A kind of citric acid tropsch imatinib crystal-form compound and preparation method thereof | |
EP3008071B1 (en) | Polymorphic form of icotinib and uses thereof | |
CN105646461B (en) | S configuration 4- (substituted anilinic) quinazoline derivant and its preparation method and application | |
WO2022268063A1 (en) | Crystal form of pyrimidine derivative and preparation method therefor | |
CN101497640B (en) | Novel crystal form of clofarabine | |
WO2024051771A1 (en) | Crystal form of five-membered and six-membered heterocyclic compound, preparation method therefor, and use thereof | |
CN108658945A (en) | A kind of Antitubulin(VDA-1)A crystal forms | |
CN106188017B (en) | R configuration 4- (substituted anilinic) quinazoline derivant and its preparation method and application | |
CN104470929B (en) | The crystal form of Conmana and its application | |
WO2015161152A1 (en) | Polymorphic forms and co-crystals of a c-met inhibitor | |
TWI596098B (en) | Polymorphic forms of icotinib maleate and uses thereof | |
TW202140487A (en) | Salts and solid forms and processes of preparing a pi3k inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160713 |